Ganirelix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ganirelix
- Ganirelix: From Ovarian Stimulation Support (Premature Ovulation Prevention) to Hypertrichosis
Ganirelix: From Ovarian Stimulation Support (Premature Ovulation Prevention) to Hypertrichosis
One-Sentence Summary
Ganirelix is a GnRH receptor antagonist used to prevent premature ovulation in women undergoing ovarian stimulation during fertility treatment. The TxGNN model predicts it may be effective for hypertrichosis, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is purely computational and should be treated as a hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prevention of premature ovulation in women undergoing ovarian stimulation during fertility treatment (from pharmacology data; the Singapore licence text is blank) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ganirelix blocks the GnRH receptor (GNRHR) in the pituitary. This rapidly suppresses LH and FSH and, downstream, gonadal sex steroids. Detailed mechanism of action data is not available in the data compiled for this report, but the receptor-level pharmacology is well established.
The link to hypertrichosis is weak. Hypertrichosis is often androgen-independent (congenital, drug-induced, or genetic forms), so suppressing the gonadal axis would not be expected to help. The high TxGNN score (0.9998) reflects proximity in a knowledge graph, probably through shared hair-phenotype associations, and is not supported by any clinical or literature evidence.
The other top-ranked predictions (Ambras syndrome, malformation syndromes, Dandy-Walker–related syndromes, genetic hair shaft abnormalities) are mostly structural or genetic conditions with no plausible GnRH mechanism. Two lower-ranked predictions are more biologically coherent:
- Central precocious puberty (rank 9): driven by premature activation of the hypothalamic-pituitary-gonadal axis, so GnRH receptor blockade is mechanistically plausible. This is the most coherent candidate and merits a targeted literature and trial search.
- Familial male-limited precocious puberty (rank 6): closest to the drug's pharmacology, but the cause is an activating LHCGR mutation downstream of GnRH and LH, so efficacy is not expected.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN12165P | ORGALUTRAN SOLUTION FOR INJECTION 0.25 mg/0.5 ml (Vetter Pharma-Fertigung GmbH & Co. KG) | Injection | Not stated in the licence record |
Safety Considerations
Drug Interactions: Seven interaction records were found. Six are rated Moderate and involve other agents acting on the reproductive hormone axis:
- Gonadorelin
- Chorionic gonadotropin (human)
- Menotropins
- Triptorelin
- Follitropin
- Urofollitropin
The seventh is a pharmacology record confirming the GnRH receptor as the target and has no severity rating.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5), with no trials or publications and no plausible mechanism linking GnRH antagonism to hypertrichosis. Evidence is insufficient to justify further investment in this indication.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, to enable safety screening
- Detailed mechanism of action data (MOA) from DrugBank
- A targeted literature and trial search for GnRH antagonists in central precocious puberty, the most mechanistically coherent candidate
- Any clinical or preclinical evidence linking GnRH antagonism to hair growth disorders, if hypertrichosis is to remain under consideration
- Route compatibility and similarity-to-original-indication assessments, both still pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.